SCHEMBL983515

SCHEMBL983515

COCCn1ncc(Cl)cc1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
MAOB P27338 2/20 0.39
MAOA P21397 1/20 0.39
CYP1A2 P05177 8/20 0.37
CYP3A4 P08684 6/20 0.37
CYP2C9 P11712 4/20 0.37
TSHR P16473 3/20 0.37
CYP2C19 P33261 3/20 0.37
MDM4 O15151 1/20 0.35
MDM2 Q00987 1/20 0.35
HCAR3 P49019 1/20 0.34
HSD17B10 Q99714 6/20 0.34
CASP1 P29466 4/20 0.34
ALOX15 P16050 3/20 0.34
CASP7 P55210 3/20 0.34
HPGD P15428 2/20 0.34
NR3C1 P04150 1/20 0.34
CLK4 Q9HAZ1 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24184142 0.81 ALDH1A1 (0.41) ALDH1A1MAOBMAOACYP1A2CYP3A4
SCHEMBL980667 0.80 CYP1A2 (0.40) ALDH1A1MAOBMAOACYP1A2CYP3A4
SCHEMBL20974177 0.78 KAT2B (0.50) TSHRMEN1KMT2AKAT2B
SCHEMBL978625 0.77 KMT2A (0.44) ALDH1A1TSHRHSD17B10HPGDMEN1
SCHEMBL31014921 0.76 KMO (0.38) ALDH1A1CYP1A2CYP3A4CYP2C19HSD17B10
SCHEMBL20973916 0.73 KMO (0.42) ALDH1A1CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL978628 0.73 HTT (0.53) ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL20973814 0.73 KMO (0.56) MEN1KMT2A
SCHEMBL26915819 0.72 F2RL1 (0.33)
SCHEMBL981321 0.71 RAB9A (0.48) ALDH1A1HSD17B10HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235687-A1 LRRK2 INHIBITORS Brenig Therapeutics, Inc. (US) 2025-11-13 WO disclosed
EP-2456765-B1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-05-01 EP disclosed
US-8334287-B2 Imidazoles HOFFMANN-LA ROCHE INC. (US) 2012-12-18 US disclosed
EP-2456765-A1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-05-30 EP disclosed
WO-2011006910-A1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-01-20 WO disclosed
US-20110015202-A1 IMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015202-A1 IMIDAZOLES GRM5, GRM1, GRIK5 ALDH1A1 1642/4885MAOB 2401/4885MAOA 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.